Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
about
Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence.Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral LeishmaniasisCoating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responsesAlterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis PatientsMonitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]Terpenes increase the lipid dynamics in the Leishmania plasma membrane at concentrations similar to their IC50 valuesChemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensisDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.In vitro activity of the hydroethanolic extract and biflavonoids isolated from Selaginella sellowii on Leishmania (Leishmania) amazonensis.Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasisLow versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis.Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment.Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.Plants with anti-Leishmania activity: Integrative review from 2000 to 2011.Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning TravelersEfficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials.Kaurenoic Acid Possesses Leishmanicidal Activity by Triggering a NLRP12/IL-1β/cNOS/NO PathwayLeishmaniasis in the United States: treatment in 2012Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole.The development and clinical evaluation of second-generation leishmaniasis vaccines.Identification of Th1/Th2 regulatory switch to promote healing response during leishmaniasis: a computational approach.Synthesis and structure-activity relationships of lansine analogues as antileishmanial agents.Zinc(II)-Dipicolylamine Coordination Complexes as Targeting and Chemotherapeutic Agents for Leishmania major.HSP70 of Leishmania amazonensis alters resistance to different stresses and mitochondrial bioenergeticsStrychnos pseudoquina and Its Purified Compounds Present an Effective In Vitro Antileishmanial ActivityFirst Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report.Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.Development of a scoring system using a statistical model to predict cure status in patients with cutaneous leishmaniasis.Nonneoplastic mucocutaneous lesions in organ transplant recipients.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives.Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous LeishmaniasisMeglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
P2860
Q27022964-AED6D8E5-EB79-4D5F-81D6-1CEBF025BAA3Q27318412-4DD0CAEC-5404-47B2-9D6F-F79BD9AF4455Q28383050-9A7BECDA-ECE1-4582-BB29-72E745CE33ECQ28468456-BACD6004-7E8F-4053-A5C3-3E1B8CAF6C5EQ28480699-2DA5D1A7-A398-4298-9E2A-18EBE3CFD211Q28541719-758287FA-E053-4851-B946-8EAEA9628371Q28544030-A1F6B457-37E0-43A7-9E8A-9CC909861E32Q30275257-77EE01E0-BF18-4D00-9E48-189D04434897Q33570722-269F1162-C490-4B08-823A-EED93002B47CQ33587086-AE6005D3-9D66-46CD-93CF-28F65FDA9C88Q33602811-F7C71A2D-E137-4563-BBAF-3440F61B5101Q33739398-3DCDEEE8-BB4A-4B7B-85E6-27650A491AE9Q34058373-474E3269-CFB8-4EE5-A993-DFDE8EDE8BC0Q34229998-A0743A23-4679-4D8F-80F0-B2243BDB3113Q34474454-D5AAD2A3-1462-4BC3-B8D1-43AE0CED2F11Q34662190-175D9492-3A00-46BA-9E68-2066C823E3F2Q34700686-FDC7D021-3329-455B-BBD8-9C19B05A7E5BQ34901330-49EF23BF-B662-42E4-9CE0-0EFD514C9E47Q35180338-29894AF7-FDB6-400C-AE82-90C6FE02299AQ35640976-C64102B0-D237-42B4-A78D-0A32B63EDF14Q35649691-CB1C5BB3-FA82-4F93-ACA9-48E85AF4E39FQ35771790-BD03498F-991F-44F9-A48C-15D8D7386254Q35977108-8DDE3BD3-C8BF-4C17-B7E5-726CBFF9FAFEQ35986733-34AD4724-A6F0-485D-8C34-53F5AE2EB18BQ36339132-57F5233E-681E-4A2B-8843-DA00065BCF53Q36589075-2A015E6A-C8A2-4996-8CA7-F7DF86D974F8Q36887740-EEC881B2-CC7E-4663-BEE9-D0FB178839C2Q37118526-66A4CE70-89F0-4A91-AF65-4B115D137D10Q37249872-0DF0DC75-2A63-4A11-BA2F-2F039D38DDBDQ37491894-A8AAE7D7-474E-4EAA-8834-D6DC7C5258CCQ37544427-B0B4F4DF-E86B-46BA-87EC-91002DD1B467Q37639367-8E4F162D-DF73-49F4-8A3B-F50E0619CFA3Q37715238-970708CC-503D-40A7-8D75-3A3406C9C5D8Q37909506-28FFFBF8-7B88-46E9-9758-93FF186340EBQ38136837-71D8982B-202F-47C1-8D57-76DE40F38597Q38154347-4FB02946-8767-4346-8F51-7144981EFD42Q38511211-153582C1-9714-476A-95A2-736851FBA543Q38653256-087AF5CE-6B00-4BBE-80B7-951574E0B005Q38875177-768A4983-57AC-42E9-AE2E-6A6E765E5509Q38892600-632E6B9C-A7D7-47F4-B890-8AA0BCC297AB
P2860
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systematic review of the adver ...... is treatment in the New World.
@en
Systematic review of the adver ...... is treatment in the New World.
@nl
type
label
Systematic review of the adver ...... is treatment in the New World.
@en
Systematic review of the adver ...... is treatment in the New World.
@nl
prefLabel
Systematic review of the adver ...... is treatment in the New World.
@en
Systematic review of the adver ...... is treatment in the New World.
@nl
P2093
P1433
P1476
Systematic review of the adver ...... sis treatment in the New World
@en
P2093
Armando O Schubach
Carlos A Andrade
Luiz F Oliveira
Maria M Martins
Mauro C Marzochi
Raquel V Oliveira
P356
10.1016/J.ACTATROPICA.2011.02.007
P577
2011-03-21T00:00:00Z